Crossover RCT of TAMER Lenses in Myopia Control

Shanghai Eye Disease Prevention and Treatment Center

Status: Enrolling

Conditions: Myopia; Progressive

Treatments: Device: SV lenses; Device: TAMER Lens Spectacle

Study type: Interventional

Funder types: Other

Identifiers

NCT06329986

SEDPTC20240109

Details and patient eligibility

About

This study is a prospective, randomized, crossover clinical trial with a planned proposed enrollment of 120 Chinese male and female subjects aged 6-12 years without systemic or ocular diseases to follow up their cycloplegic equivalent spherical lens power and other relevant indices in order to determine the role of TAMER lenses in myopia control as compared to singlie vision lenses.

Enrollment: 120 estimated patients

Sex: All

Ages: 6 to 12 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Race: Chinese children and adolescents.
• Age 6-12 years, gender unrestricted.
• Cycloplegic refraction SER: -0.75DS~-5.0DS in both eyes.
• Best corrected visual acuity of both eyes reaches 0.8 (0.00 logMAR).
• Cylinder power and astigmatism are no more than 1.5D.
• During the study period, willing to wear glasses provided by the researcher only and without additional interventions.
• Willing to be randomly assigned.
• Able to sign an informed consent form with the accompaniment and understanding of parents or guardians.

Exclusion criteria

• Allergic or intolerant to medications used for cycloplegia.
• Received any nearsightedness treatment such as atropine, rigid gas permeable contact lens, bifocal/progressive lens, red light therapy, or acupuncture within half a year before the study.
• Diagnosed with any eye disease other than nearsightedness, including strabismus, corneal diseases, conjunctival or eyelid damage or other conditions (such as keratoconus, herpes simplex keratitis, etc.).
• History of eye surgery (including strabismus correction surgery).
• Eye or systemic diseases that might be associated with nearsightedness or its progression, such as Marfan syndrome, retinopathy of prematurity, diabetes, etc.
• Anatomical or dermatological factors that may interfere with the wearing of spectacle frames.
• Other reasons that the researcher deems inappropriate for the participant to be included in the study, such as excessively high expectations for the effectiveness of defocus lenses, or plans to use other nearsightedness intervention strategies simultaneously with the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind

---

120 participants in 2 patient groups

Group A

Experimental group

Description:

TAMER lenses are used first for 6 months, followed by SV lenses for 6 months.

Treatment:

Device: SV lenses

Device: TAMER Lens Spectacle

Group B

Experimental group

Description:

SV lenses are used first for 6 months, followed by TAMER lenses for 6 months.

Treatment:

Device: SV lenses

Device: TAMER Lens Spectacle